These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31023027)

  • 1. Prima-1 and APR-246 in Cancer Therapy.
    Zatloukalová P; Galoczová M; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDM2 and HDMX Proteins in Human Cancer.
    Hároníková L; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
    Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
    Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
    Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
    Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.
    Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Strömblad S
    Cell Cycle; 2011 Jan; 10(2):301-7. PubMed ID: 21239882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of HSP70 in Cancer and its Exploitation as a Therapeutic Target.
    Martinková V; Trčka F; Vojtěšek B; Müller P
    Klin Onkol; 2018; 31(Suppl 2):46-54. PubMed ID: 31023024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
    Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
    Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible Usage of p63 in Bioptic Diagnostics.
    Galoczová M; Nenutil R; Coates P; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):27-31. PubMed ID: 31023021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
    Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H
    Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
    Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
    Br J Haematol; 2004 Nov; 127(3):285-91. PubMed ID: 15491287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
    Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
    Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.